We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+0.59%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$266M
AUM Growth
+$34.2M
Cap. Flow
+$31.7M
Cap. Flow %
11.9%
Top 10 Hldgs %
46.64%
Holding
93
New
15
Increased
28
Reduced
14
Closed
6

Top Buys

Rank Stock Value
1
ELOX
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
+$3.95M
2
GNCA
Genocea Biosciences, Inc.
GNCA
+$2.53M
3
AUTL
Autolus Therapeutics
AUTL
+$2.24M
4
EPZM
Epizyme, Inc
EPZM
+$2.23M
5
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$2.16M

Top Sells

Rank Stock Value
1
VBIV
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
+$1.59M
2
ADXS
Advaxis Inc
ADXS
+$1.2M
3
ABUS icon
Arbutus Biopharma
ABUS
+$884K
4
SVRA icon
Savara
SVRA
+$813K
5
MRSN
Mersana Therapeutics
MRSN
+$603K

Sector Composition

Rank Sector Weight
1 Healthcare 91.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGTC
51
DELISTED
Applied Genetic Technologies Corporation
AGTC
$1.36M 0.51%
359,190
– –
JNJ icon
52
Johnson & Johnson
JNJ
$617B
$1.31M 0.49%
9,400
– –
FATE icon
53
Fate Therapeutics
FATE
$293M
$1.22M 0.46%
+60,031
New +$1.08M
MORF
54
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$1.19M 0.45%
+60,000
New +$1.13M
MRSN
55
DELISTED
Mersana Therapeutics
MRSN
$1.11M 0.42%
11,009
-5,123
-32% -$603K
NTUS
56
DELISTED
Natus Medical Inc
NTUS
$1.1M 0.41%
42,900
– –
DERM
57
DELISTED
Dermira, Inc.
DERM
$994K 0.37%
104,000
+32,500
+45% +$350K
PRVL
58
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$990K 0.37%
+75,000
New +$1.09M
KURA icon
59
Kura Oncology
KURA
$826M
$930K 0.35%
47,242
+10,684
+29% +$177K
MGNX icon
60
MacroGenics
MGNX
$240M
$849K 0.32%
50,000
– –
SPRO icon
61
Spero Therapeutics
SPRO
$69.5M
$806K 0.3%
70,000
– –
INSM icon
62
Insmed
INSM
$22B
$768K 0.29%
+30,000
New +$836K
MDGL icon
63
Madrigal Pharmaceuticals
MDGL
$11.4B
$692K 0.26%
6,600
– –
ASMB icon
64
Assembly Biosciences
ASMB
$516M
$682K 0.26%
4,214
– –
OBSV
65
DELISTED
ObsEva SA Ordinary Shares
OBSV
$564K 0.21%
49,848
+6,440
+15% +$81.1K
GRTS
66
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$557K 0.21%
+50,000
New +$572K
KALV
67
DELISTED
KalVista Pharmaceuticals
KALV
$548K 0.21%
24,725
+1,500
+6% +$35.2K
URGN icon
68
UroGen Pharma
URGN
$2B
$539K 0.2%
15,000
– –
RDUS
69
DELISTED
Radius Health, Inc.
RDUS
$536K 0.2%
22,000
-20,000
-48% -$437K
MASI
70
DELISTED
Masimo
MASI
$446K 0.17%
3,000
– –
ALEC icon
71
Alector
ALEC
$180M
$440K 0.17%
23,166
-25,897
-53% -$526K
RIGL icon
72
Rigel Pharmaceuticals
RIGL
$704M
$359K 0.13%
13,760
– –
STRO icon
73
Sutro Biopharma
STRO
$411M
$358K 0.13%
3,149
– –
CDTX
74
DELISTED
Cidara Therapeutics
CDTX
$357K 0.13%
10,638
– –
LRMR icon
75
Larimar Therapeutics
LRMR
$398M
$340K 0.13%
23,792
-3,875
-14% -$103K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return

DAFNA Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, DAFNA Capital Management held 93 positions worth $266M, up 15% from $232M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

DAFNA Capital Management deployed $31.7M of net new capital in Q2 2019, opening 15 new positions and adding to 28 existing holdings. Its largest new stake was Eloxx Pharmaceuticals, Inc. Common Stock: 9,375 shares worth $3.74M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier.

On the sell side, the largest reduction was Mersana Therapeutics, an estimated $603K trimmed.

  • DAFNA Capital Management's largest Q2 2019 buy was Eloxx Pharmaceuticals, Inc. Common Stock: 9,375 shares worth $3.74M.
  • DAFNA Capital Management added most to Genocea Biosciences, Inc. in Q2 2019, an estimated $2.53M increase.
  • DAFNA Capital Management's biggest Q2 2019 reduction was Mersana Therapeutics, cutting an estimated $603K.
  • DAFNA Capital Management fully exited VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2019, selling an estimated $1.59M.
  • DAFNA Capital Management's ten largest holdings make up 47% of its $266M portfolio in Q2 2019.
  • DAFNA Capital Management opened 15 new positions and closed 6 in Q2 2019.
  • DAFNA Capital Management's portfolio value rose 15% quarter-over-quarter to $266M.

Based on DAFNA Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.